Presseportal.de - Ergebnis der Suchanfrage nach Meerbuschhttps://www.presseportal.dehttps://www.presseportal.de/suche.htx?q=MeerbuschPresseportal - Deutschlands umfassende Datenbank für Presseinformationen in Text, Bild, Ton und Video - ein Service der dpa-Tochter news aktuellde-denews aktuell GmbHhttps://www.presseportal.de/images/logos/logo-de-250.jpgPresseportal.de - Ergebnis der Suchanfrage nach Meerbuschhttps://www.presseportal.dehttps://www.presseportal.de/suche.htx?q=Meerbuschinfo@presseportal.de (presseportal.de)Sat, 25 Jul 2026 05:29:03 +0200Mon, 12 Jul 2021 11:30:00 +0200Meerbusch6Ansgar Eschkötter Joins Senior Management Team of the PS GroupSemdor Pharma Group: Meerbusch (ots) - Effective July 2021, Ansgar Eschkötter will strengthen the management of the PS Group, which consists of PB Pharma, PS Pharma and PS Marketing & Outsourcing GmbH. Along with Cannamedical Pharma, the PS Group forms the Semdor ...https://www.presseportal.de/pm/151877/4965963?langid=2Mon, 12 Jul 2021 11:30:00 +0200https://www.presseportal.de/pm/151877/4965963?langid=2 Semdor Pharma Group [Newsroom]
Meerbusch (ots) - Effective July 2021, Ansgar Eschkötter will strengthen the management of the PS Group, which consists of PB Pharma, PS Pharma and PS Marketing & Outsourcing GmbH. Along with Cannamedical Pharma, the PS Group forms the Semdor ... Lesen Sie hier weiter...

Original-Content von: Semdor Pharma Group, übermittelt durch news aktuell

]]>Wirtschaftinfo@presseportal.de (presseportal.de)Semdor Pharma GroupSemdor Pharma adds Global Pharmaceutical Executive Rolf Hoffmann to its Board of DirectorsSemdor Pharma Group: Cologne (ots) - 30-year pharma veteran Rolf Hoffmann, formerly senior global executive at Amgen and Eli Lilly, joins Semdor Pharma as investor and commercial expert. Semdor Pharma Group announced today that it has added Rolf Hoffmann, a seasoned ...https://www.presseportal.de/pm/151877/4876503?langid=2Mon, 29 Mar 2021 13:38:28 +0200https://www.presseportal.de/pm/151877/4876503?langid=2 Semdor Pharma Group [Newsroom]
Cologne (ots) - 30-year pharma veteran Rolf Hoffmann, formerly senior global executive at Amgen and Eli Lilly, joins Semdor Pharma as investor and commercial expert. Semdor Pharma Group announced today that it has added Rolf Hoffmann, a seasoned ... Lesen Sie hier weiter...

Original-Content von: Semdor Pharma Group, übermittelt durch news aktuell

]]>Wirtschaftinfo@presseportal.de (presseportal.de)Semdor Pharma GroupMerger: Newly-formed Semdor Pharma Group becomes one of Europe's leading pharmaceutical companies for narcotics and medical cannabisSemdor Pharma Group: Cologne (ots) - ++ PS Group and Cannamedical Pharma combine to form Semdor Group ++ ++ With 160 employees in Germany and >65M EUR in annual revenue, Semdor comprises a leading narcotics services and product platform in the European pain therapy ...https://www.presseportal.de/pm/151877/4813508?langid=2Fri, 15 Jan 2021 15:15:33 +0100https://www.presseportal.de/pm/151877/4813508?langid=2 Semdor Pharma Group [Newsroom]
Cologne (ots) - ++ PS Group and Cannamedical Pharma combine to form Semdor Group ++ ++ With 160 employees in Germany and >65M EUR in annual revenue, Semdor comprises a leading narcotics services and product platform in the European pain therapy ... Lesen Sie hier weiter...

Original-Content von: Semdor Pharma Group, übermittelt durch news aktuell

]]>Gesundheit / Medizininfo@presseportal.de (presseportal.de)Semdor Pharma GroupEANS-General Meeting: K+S Aktiengesellschaft / Announcement convening the general meetingK+S Aktiengesellschaft: issuer: K+S Aktiengesellschaft Bertha-von-Suttner-Straße 7 D-34131 Kassel phone: +49 (0)561 9301-1460 FAX: +49 (0)561 9301-2425 mail: investor-relations@k-plus-s.com WWW: http://www.k-plus-s.com sector: Chemicals ISIN: DE000KSAG888 indexes: DAX, ...https://www.presseportal.de/pm/16234/2443447?langid=2Tue, 02 Apr 2013 15:29:55 +0200https://www.presseportal.de/pm/16234/2443447?langid=2 K+S Aktiengesellschaft [Newsroom]
issuer: K+S Aktiengesellschaft Bertha-von-Suttner-Straße 7 D-34131 Kassel phone: +49 (0)561 9301-1460 FAX: +49 (0)561 9301-2425 mail: investor-relations@k-plus-s.com WWW: http://www.k-plus-s.com sector: Chemicals ISIN: DE000KSAG888 indexes: DAX, ... Lesen Sie hier weiter...

Original-Content von: K+S Aktiengesellschaft, übermittelt durch news aktuell

]]>Finanzeninfo@presseportal.de (presseportal.de)K+S Aktiengesellschafteuro adhoc: Marseille-Kliniken AG / Financial Figures/Balance Sheet / - Increase in turnover in the financial year 2007/2008 to EUR 228.1 m - Consolidated net income reaches EUR 1.14 per share - Surge in profits in the Rehabilitation segmentMarseille-Kliniken AG: Further inquiry note: Marseille-Kliniken AG Axel Hölzer CEO Alte Jakobstraße 79/80 10709 Berlin Germany Tel.: +49 30 / 246 32-400 Fax: +49 30 / 246 32-401 www.marseille-kliniken.com Hillermann Consulting Christian Hillermann Investor Relations ...https://www.presseportal.de/pm/7994/1292377?langid=2Fri, 31 Oct 2008 08:36:21 +0100https://www.presseportal.de/pm/7994/1292377?langid=2 Marseille-Kliniken AG [Newsroom]
Further inquiry note: Marseille-Kliniken AG Axel Hölzer CEO Alte Jakobstraße 79/80 10709 Berlin Germany Tel.: +49 30 / 246 32-400 Fax: +49 30 / 246 32-401 www.marseille-kliniken.com Hillermann Consulting Christian Hillermann Investor Relations ... Lesen Sie hier weiter...

Original-Content von: Marseille-Kliniken AG, übermittelt durch news aktuell

]]>Finanzeninfo@presseportal.de (presseportal.de)Marseille-Kliniken AG